Cas:438461-39-3 iodomethylcyclooctane manufacturer & supplier

We serve Chemical Name:iodomethylcyclooctane CAS:438461-39-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

iodomethylcyclooctane

Chemical Name:iodomethylcyclooctane
CAS.NO:438461-39-3
Synonyms:Cyclooctylmethyl iodide
Molecular Formula:C9H17I
Molecular Weight:252.13600
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:255.7ºC at 760 mmHg
Density:1.386g/cm3
Index of Refraction:1.511
PSA:
Exact Mass:252.03700
LogP:3.78190

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Cyclooctylmethyl iodide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Cyclooctylmethyl iodide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Cyclooctylmethyl iodide Use and application,Cyclooctylmethyl iodide technical grade,usp/ep/jp grade.


Related News: The Ballina facility was first established in 1974 and was acquired by Charles River in 2002. Over the years it has added to its capabilities offering a comprehensive package of GMP services in support of recombinant biologics, vaccines, cell and gene therapies, biosimilars, and medical devices. Charles River now employs 230 people at two facilities in Ireland: the site in Ballina Co. Mayo which focuses on biologics testing, and a site in Dublin, established in 2017, which serves as the EMEA and APAC headquarters for the Company’s Microbial Solutions division. N-(3-bromo-5-phenylpyrazolo[1,5-a]pyridin-7-yl)isonicotinamide manufacturers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. 8-(2-Methoxyethylidene)-2-methyl-3,5,7,8-tetrahydrothiopyrano-[4,3-d]pyrimidin-4-one suppliers ADA-SCID is caused by a gene mutation that affects a critical protein called adenosine deaminase, which is needed to keep toxins in the body from destroying disease-fighting white blood cells. 1,3-difluoro-5-((2-fluoro-4-vinylphenyl)ethynyl)-2-(trifluoromethoxy)benzene vendor & factory.